Skip Navigation


Annals of Oncology Advance Access originally published online on September 10, 2007
Annals of Oncology 2007 18(10):1680-1684; doi:10.1093/annonc/mdm287
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/10/1680    most recent
mdm287v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Macdonald, D. A.
Right arrow Articles by Meyer, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macdonald, D. A.
Right arrow Articles by Meyer, R. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

hematologic malignancies

Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma{dagger}

D. A. Macdonald1, K. Ding1, M. K. Gospodarowicz2, W. A. Wells2, R. G. Pearcey3, J. M. Connors4, J. N. Winter5, S. J. Horning6, M. S. Djurfeldt1, L. E. Shepherd1 and R. M. Meyer1,*

1 National Cancer Institute of Canada Clinical Trials Group, Queens University, Kingston, ON
2 Princess Margaret Hospital and University of Toronto, Toronto, ON
3 Cross Cancer Institute and University of Alberta, Edmonton, AB
4 British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada
5 Feinberg School of Medicine, Northwestern University, Chicago, IL
6 Stanford University, Palo Alto, CA, USA

* Correspondence to: Dr. Ralph M. Meyer, National Cancer Institute of Canada Clinical Trials Group, Cancer Research Institute, Queens University, 10 Stuart Street, Kingston, Ontario, K7L 3N6, Canada. Tel: +1 613-533-6430; Fax: +1 613-533-6511; E-mail: RMeyer{at}ctg.queensu.ca

Background: In the National Cancer Institute of Canada Clinical Trials Group/Eastern Cooperative Oncology Group HD.6 trial, progression-free survival was better in patients randomized to therapy that included radiation, compared to doxorubicin (Adriamycin®), bleomycin, vinblastine and dacarbazine (ABVD) alone. We now evaluate patterns of progression and subsequent outcomes of patients with progression.

Patients and methods: After a median of 4.2 years, 33 patients have progressed. Two radiation oncologists determined whether sites of progression were confined within radiation fields. Freedom from second progression (FF2P) and freedom from second progression or death (FF2P/D) were compared.

Results: Reviewers agreed for the extended (kappa = 0.87) and involved field (kappa = 1.0) analyses. Progression after ABVD alone was more frequently confined within both the extended (20/23 vs. 3/10; P = 0.002) and involved fields (16/23 vs. 2/10; P = 0.02). There was no difference in FF2P between groups [5-year estimate 99% (radiation) versus 96% (ABVD alone)] [hazard ratio (HR) = 3.14, 95% confidence interval (CI) 0.63–15.6; P = 0.14]; the 5-year estimates of FF2P/D were 94% in each group (HR = 1.04, 95% CI 0.41–2.63; P = 0.93).

Conclusion: Treatment that includes radiation reduces the risk of progressive Hodgkin lymphoma in sites that receive this therapy, but we are unable to detect differences in FF2P or FF2P/D.

Key words: chemotherapy, Hodgkin, limited-stage, relapse

{dagger} For the National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. This work was presented at the 2005 Meeting of the American Society of Hematology.

Received for publication May 11, 2007. Accepted for publication May 16, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

in this issue

Ann Oncol 2007 18: 1589. [Extract] [FREE Full Text]  





Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.